Abstract
The present study was designed to elucidate the relationship between p53 and ceramide, both of which are involved in apoptotic signaling. Treatment of human glioma cells with etoposide caused apoptosis only in cells expressing functional p53. p53 activation was followed by the formation of reactive oxygen species (ROS), superoxide anion (O2−•) measured by hydroethidium oxidation into ethidium and hydrogen peroxide (H2O2) measured by oxidation of 2′,7′-dichlorofluorescin (DCFH) into 2′,7′-dichlorofluorescein (DCF), which was accompanied with ceramide generation through the activation of neutral, but not acid, sphingomyelinase. Superoxide dismutase (SOD), a selective antioxidant for O2−•, had no effects on p53 expression but inhibited ceramide generation and apoptotic cell death caused by etoposide. However, catalase, a specific antioxidant for H2O2, only weakly inhibited and sodium formate, a hydroxyl radical (• OH) scavenger, unaffected etoposide-induced apoptosis. Like etoposide-induced cell death, treatment of glioma cells with the O2−•-releasing agent, pyrogallol, induced typical apoptosis and ceramide generation even in the presence of catalase. In contrast, human glioma cells lacking functional p53, either due to mutation or the expression of E6 protein of human papillomavirus, were highly resistant to etoposide and exhibited no significant change in the ceramide level. Moreover, expression of functional p53 protein in glioma cells expressing mutant p53 using a temperature-sensitive human p53Val138 induced ceramide accumulation by the activation of neutral sphingomyelinase which was dependent on the generation of O2−•. Taken together, these results suggest that p53 may modulate ceramide generation by activation of neutral sphingomyelinase through the formation of O2−•, but not its downstream compounds H2O2 or • OH.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- A-SMase:
-
acid sphingomyelinase
- DCF:
-
2′,7′-dichlorofluorescein
- DCFH-DA:
-
2′,7′-dichlorofluorescin diacetate
- DMEM:
-
Dulbecco's modified Eagle's medium
- FBS:
-
fetal bovine serum
- GSH:
-
reduced glutathione
- H2O2:
-
hydrogen peroxide
- HE:
-
hydroethidium
- HPTLC:
-
high performance thin-layer chromatography
- HPV:
-
human papillomavirus
- MTp53ts:
-
temperature-sensitive human p53 val138 mutant
- NAC:
-
N-acetylcysteine
- N-SMase:
-
neutral and magnesium-dependent sphingomyelinase
- O2−•:
-
superoxide anion
- • OH:
-
hydroxyl radical
- PDTC:
-
pyrrolidinedithiocarbamate
- ROS:
-
reactive oxygen species
- SDS–PAGE:
-
sodium dodecylsulfate polyacrylamide gel electrophoresis
- SM:
-
sphingomyelin
- SOD:
-
superoxide dismutase
- TNF:
-
tumor necrosis factor.
References
Borek C . 1987 Br. J. Cancer 8: S74–S86
Brune B, Gotz C, Messmer UK, Sandau K, Hirvonen MR, Lapetina EG . 1997 J. Biol. Chem. 272: 7253–7258
Busciglio J, Yankner BA . 1995 Nature 378: 776–779
Buttke TM, Sandstrom PA . 1994 Immunol. Today 15: 7–10
Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R . 1994 J. Exp. Med. 180: 1547–1552
Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MKL . 1995 J. Virol. 69: 7430–7436
Dbaibo GS, Pushkareva MY, Rachid RA, Alter N, Smyth MJ, Obeid LM, Hannun YA . 1998 J. Clin. Invest. 102: 329–339
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B . 1993 Cell 75: 817–825
Frankel RH, Bayona W, Koslow M, Newcomb EW . 1992 Cancer Res. 52: 1427–1433
Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WKA . 1996 Cancer Res. 56: 694–699
Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z, Kolesnick RN . 1994 J. Exp. Med. 180: 525–535
Halbert CL, Demers GW, Galloway DA . 1991 J. Virol. 65: 473–478
Hannun YA . 1996 Science 274: 1855–1859
Hartwell LH, Kastan MB . 1994 Science 266: 1821–1828
Hollstein M, Sidransky D, Vogelstein B, Harris CC . 1991 Science 253: 49–53
Huang C, Zhang Z, Ding M, Li J, Ye J, Leonard SS, Shen H-M, Butterworth L, Lu Y, Costa M, Rojanasakul Y, Castranova V, Vallyathan V, Shin X . 2000 J. Biol. Chem. 275: 32516–32522
Jacobson MD . 1996 Trend Biochem. Sci. 21: 83–86
Jaffrézou J, Levade T, Bettaïeb A, Andrieu N, Bezombes C, Maestre N, Vermeersch S, Rousse A, Laurent G . 1996 EMBO J. 15: 2417–2424
Jayadev S, Liu B, Bielawska AE, Lee JY, Nazaire F, Pushkareva MYU, Obeid LM, Hannun YA . 1995 J. Biol. Chem. 270: 2047–2052
Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T . 1996 Proc. Natl. Acad. Sci. USA 93: 11848–11852
Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, Ishibashi M . 1997 Proc. Natl. Acad. Sci. USA 94: 11612–11616
Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ . 1998 Nature 396: 84–88
Klingelhutz AJ, Foster SA, McDougall JK . 1996 Nature 380: 79–82
Kramer W, Drutsa V, Jansen HW, Kramer B, Pflugfelder M, Fritz HJ . 1984 Nucl. Acids Res. 12: 9441–9456
Kroemer G, Zamzami N, Susin SA . 1997 Immunol. Today 18: 45–51
Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB . 1992 Proc. Natl. Acad. Sci. USA 89: 7491–7495
Lang D, Miknyoczki SJ, Huang L, Ruggeri BA . 1998 Oncogene 16: 1593–1602
Lennon SV, Martin SJ, Cotter TG . 1991 Cell Prolif. 24: 203–214
Levine AJ . 1997 Cell 88: 323–331
Li PF, Dietz R, von Harsdorf R . 1999 EMBO J. 18: 6027–6036
Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE . 1992 Proc. Natl. Acad. Sci. USA 89: 9210–9214
Liu B., Andrieu-Abadie N, Levade T, Zhang P, Obeid L, Hannun YA . 1998 J. Biol. Chem. 273: 11313–11320
Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T . 1993 Nature 362: 847–849
Michalovitz D, Halevy O, Oren M . 1990 Cell 62: 671–680
Moreno-Manzano V, Ishikawa Y, Lucio-Cazana J, Kitamura M . 2000 J. Biol. Chem. 275: 12684–12691
Narayanan PK, Goodwin EH, Lehnert BE . 1997 Cancer Res. 57: 3963–3971
Okazaki T, Bieloawska A, Bell RM, Hannun YA . 1990 J. Biol. Chem. 265: 15823–15831
Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B . 1996 Genes Dev. 10: 1945–1952
Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B . 1997 Nature 389: 300–305
Ramakrishnan N, Catravas GN . 1992 J. Immunol. 148: 1817–1821
Rothe G, Valet G . 1990 J. Leukoc. Biol. 47: 440–448
Sawada M, Nakashima S, Banno Y, Yamakawa H, Takenaka K, Shinoda J, Nishimura Y, Sakai N, Nozawa Y . 2000a Oncogene 19: 3508–3520
Sawada M, Nakashima S, Banno Y, Yamakawa H, Hayashi K, Takenaka K, Nishimura Y, Sakai N, Nozawa Y . 2000b Cell Death Differ. 7: 761–772
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM . 1993 Cell 75: 495–505
Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR . 2000 J. Biol. Chem. 275: 7337–7342
Schwandner R, Wiegmann K, Bernardo K, Kreder D, Kronke M . 1998 J. Biol. Chem. 273: 5916–5922
Tepper AD, Cock JG, de Vries E, Borst J, van Blitterswijk WJ . 1997 J. Biol. Chem. 272: 24308–24312
Tepper AD, de Vries E, van Blitterswijk WJ, Borst J . 1999 J. Clin. Invest. 103: 971–978
Vayssiere JL, Petit PX, Risler Y, Mignotte B . 1994 Proc. Natl. Acad. Sci. USA 91: 11752–11756
Venable ME, Lee JY, Smyth MJ, Bielawska A, Obeid LM . 1995 J. Biol. Chem. 270: 30701–30708
Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF, Sikorska M . 1991 Cancer Res. 51: 1078–1085
Xie YW, Kaminski PM, Wolin MS . 1998 Circ. Res. 82: 891–897
Yoshimura S, Sakai H, Ohguchi K, Nakashima S, Banno Y, Nishimura Y, Sakai N, Nozawa Y . 1997 J. Neurochem. 69: 713–720
Yoshimura S, Banno Y, Nakashima S, Takenaka K, Sakai H, Nishimura Y, Sakai N, Shimizu S, Eguchi Y, Tsujimoto Y, Nozawa Y . 1998 J. Biol. Chem. 273: 6921–6927
Yoshimura S, Banno Y, Nakashima S, Hayashi K, Yamakawa H, Sawada M, Sakai N, Nozawa Y . 1999 J. Neurochem. 73: 675–683
Zhang P, Liu B, Jenkins GM, Hannun YA, Obeid LM . 1997 J. Biol. Chem. 272: 9609–9612
Acknowledgements
We are grateful to Dr T Takahashi (Aichi Cancer Center, Japan) for wild-type human p53 plasmid and to Dr Y Takeuchi (Chester Beatty Laboratories, ICR, UK) for FLYA13 cells. We also thank F Yang for technical assistance. This work was supported in part by Grants-in-Aid for Scientific Research from The Ministry of Education, Science, Sports and Culture of Japan, The Naito Foundation and ONO Medical Research Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sawada, M., Nakashima, S., Kiyono, T. et al. p53 regulates ceramide formation by neutral sphingomyelinase through reactive oxygen species in human glioma cells. Oncogene 20, 1368–1378 (2001). https://doi.org/10.1038/sj.onc.1204207
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204207
Keywords
This article is cited by
-
A defect in mitochondrial fatty acid synthesis impairs iron metabolism and causes elevated ceramide levels
Nature Metabolism (2023)
-
Tumor suppressor p53 links ceramide metabolism to DNA damage response through alkaline ceramidase 2
Cell Death & Differentiation (2017)
-
Embryonic defence mechanisms against glucose-dependent oxidative stress require enhanced expression of Alx3 to prevent malformations during diabetic pregnancy
Scientific Reports (2017)
-
Global Changes in Lipid Profiles of Mouse Cortex, Hippocampus, and Hypothalamus Upon p53 Knockout
Scientific Reports (2016)
-
P53-dependent upregulation of neutral sphingomyelinase-2: role in doxorubicin-induced growth arrest
Cell Death & Disease (2015)